Economic evaluation of sunitinib malate in second-line treatment of metastatic renal cell carcinoma in Finland
- 29 February 2008
- journal article
- research article
- Published by Elsevier BV in Clinical Therapeutics
- Vol. 30 (2), 382-392
- https://doi.org/10.1016/j.clinthera.2008.02.013
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Sunitinib malate for the treatment of solid tumours: a review of current clinical dataExpert Opinion on Investigational Drugs, 2006
- Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell CarcinomaJournal of Clinical Oncology, 2006
- Parametric modelling of cost data in medical studiesStatistics in Medicine, 2004
- Comprehensive decision analytical modelling in economic evaluation: a Bayesian approachHealth Economics, 2004
- Prognostic Factors for Survival in Previously Treated Patients With Metastatic Renal Cell CarcinomaJournal of Clinical Oncology, 2004
- Does NICE have a cost‐effectiveness threshold and what other factors influence its decisions? A binary choice analysisHealth Economics, 2004
- Interferon Alfa-2b Three Times Daily and Thalidomide in the Treatment of Metastatic Renal Cell CarcinomaJournal of Clinical Oncology, 2003
- Renal cell carcinoma: current status and future directionsCritical Reviews in Oncology/Hematology, 2003
- Probabilistic Analysis of Cost-Effectiveness Models: Choosing between Treatment Strategies for Gastroesophageal Reflux DiseaseMedical Decision Making, 2002
- SYSTEMIC THERAPY FOR RENAL CELL CARCINOMAJournal of Urology, 2000